Page 3 - மார்பக மருத்துவ புற்றுநோயியல்+நிபுணர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

email article
Triple-negative breast cancer (TNBC) has been one of the most difficult cancers to treat mainly because it doesn t offer much in the way of therapeutic targets, but that is starting to change.
Triple-negative breast cancer, for many years at least, has not had a clear target that we can attack, Debu Tripathy, MD, chairman of the Department of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston, told
MedPage Today. It has always been a challenging subtype to treat.
For hormone-receptor positive cancers we can use endocrine therapies, he explained. For HER2-positive cancers we can use HER2-targeted therapies, and these are quite effective. We still use chemotherapy in many of these cases, but we get an added advantage with the addition of the targeted agents. But for triple-negative, we haven t been able to find a very specific, unique target that can be harnessed as a drug. ....

United States , Dana Farber Cancer Institute , Nancy Lin , Andrew Brenner , Sstephen Schleicher , Mays Cancer Center , Department Of Breast Medical Oncology , University Of Texas Md Anderson Cancer Center , Ut Health San Antonio , Oncology Group , European Society For Medical Oncology , Breast Medical Oncology , Cancer Center , Tennessee Oncology , European Society , Medical Oncology , Metastatic Breast Cancer Program , San Antonio , Response Assessment , Southwest Oncology Group , ஒன்றுபட்டது மாநிலங்களில் , டானா ஃபார்‌பர் புற்றுநோய் நிறுவனம் , நான்சி லின் , ஆண்ட்ரூ ப்ரென்னர் , ஸ்டீபன் ஸ்க்லீச்சர் , மேஸ் புற்றுநோய் மையம் ,